Navigation Links
BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
Date:12/5/2008

BELLUS Health Receives NASDAQ Deficiency Notice Relating to Market Value

------------------------------------------------------------------------

LAVAL, QC, Dec. 5 /PRNewswire-FirstCall/ - BELLUS Health Inc. (NASDAQ: BLUS; TSX: BLU) announces that in light of continuing significant fluctuations in world capital markets, the Company is preparing to voluntarily delist from the NASDAQ Capital Market, while continuing to maintain a full listing on the Toronto Stock Exchange (TSX: BLU). In connection with its NASDAQ listing, the Company received a Deficiency Letter dated December 1, 2008, from the NASDAQ Staff stating that, for 10 consecutive trading days, the market value of the Company's listed securities had been below the minimum $35,000,000 requirement for continued inclusion on the NASDAQ Capital Market under Marketplace Rule 4310(c)(3)(B), and that the Company would have until December 31, 2008 to regain compliance. The Company's listing on the Toronto Stock Exchange is not affected by the notice received from NASDAQ, nor by the decision to voluntarily delist from this U.S. exchange. The Company expects the delisting to take effect in early January 2009. The Company will continue to be subject to the filing and other obligations of the U.S. securities laws applicable to non-U.S. reporting companies during 2009.

The decision to voluntarily delist is reinforced by extreme short-term volatility in stock markets and accordingly, in the Company's market value. Daily fluctuations in the price of BELLUS Health shares have resulted in the Company moving in and then out of compliance with NASDAQ requirements over the past weeks. In light of the recent correspondence with NASDAQ, BELLUS Health has determined that the perceived benefit of being listed on NASDAQ no longer merits the capital and human investment involved in maintaining the listing.

The Company has received confirmation from holders of at least a majority in value of the $42,085,000 aggregate principal amount of 6% convertible senior notes issued in November 2006 (the Notes) of their intention to consent to an amendment to the Trust Indenture governing the Notes, which would permit delisting from NASDAQ.

Listing of the Company's securities on NASDAQ is a condition to drawdown under the terms of the equity line of credit facility concluded with Cityplatz Limited in August of 2006, as amended (the Credit Facility). Delisting its common stock from NASDAQ will mean that the Company will no longer be able to avail itself of funds under the Credit Facility. Based on recent trading prices and volumes, the total amount that could potentially be drawn down under the Credit Facility is approximately US$1 million on an annual basis.

About BELLUS Health

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1 877 680 4500 or visit the Web Site at www.bellushealth.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.

CONTACT: Lise Hebert, Ph.D., Vice President, Corporate Communications, (450) 680-4572, lhebert@bellushealth.com


'/>"/>
SOURCE BELLUS HEALTH INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
2. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
3. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
4. BELLUS Health provides update on activities
5. BELLUS Health announces closing of Innodia acquisition
6. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
7. BELLUS HEALTH reports results for first quarter of fiscal 2008
8. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
9. Health Care Without Harm, WHO Announce Partnership for Global Reduction of Mercury-Based Medical Devices
10. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
11. Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: